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Abstract
 
The prototranscription factor p100 represents an intersection of the NF-
 
 
 
B and I
 
 
 
B families,
potentially serving as both the precursor for the active NF-
 
 
 
B subunit p52 and as an I
 
 
 
B capable
of retaining NF-
 
 
 
B in the cytoplasm. NF-
 
 
 
B–inducing kinase (NIK) controls processing of
p100 to generate p52, and thus NIK-deficient mice can be used to examine the biological effects
of a failure in such processing. We demonstrate that treatment of wild-type osteoclast precursors
with the osteoclastogenic cytokine receptor activator of NF-
 
 
 
B ligand (RANKL) increases
both expression of p100 and its conversion to p52, resulting in unchanged net levels of p100.
In the absence of NIK, p100 expression is increased by RANKL, but its conversion to p52 is
blocked, leading to cytosolic accumulation of p100, which, acting as an I
 
 
 
B protein, binds
NF-
 
 
 
B complexes and prevents their nuclear translocation. High levels of unprocessed p100 in
osteoclast precursors from NIK
 
 
 
/
 
 
 
 mice or a nonprocessable form of the protein in wild-type
cells impair RANKL-mediated osteoclastogenesis. Conversely, p100-deficient osteoclast pre-
cursors show enhanced sensitivity to RANKL. These data demonstrate a novel, biologically
relevant means of regulating NF-
 
 
 
B signaling, with upstream control and kinetics distinct from
the classical I
 
 
 
B
 
 
 
 pathway.
Key words: mice knockout • bone remodeling/physiology • MAP kinase kinase kinases • 
cultured cells/physiology • murine RANKL
 
Introduction
 
Osteoclasts (OCs) are multinucleated cells derived from
mononuclear myeloid bone marrow progenitors that express
receptor activator of NF-
 
 
 
B (RANK), the receptor for the
key osteoclastogenic cytokine RANK ligand (RANKL)
(1). Interaction of RANK with RANKL in the presence of
macrophage CSF (M-CSF) promotes OC differentiation.
Thus, deletion of the RANK, RANKL, or M-CSF genes
leads to an absence of OCs, causing osteopetrosis. Like
other members of the TNF receptor superfamily, RANK
potently activates the NF-
 
 
 
B pathway.
In the canonical NF-
 
 
 
B pathway (for reviews see refer-
ence 2, 3), ligation of a transmembrane receptor such as
RANK activates the I
 
 
 
B kinase (IKK) complex, which
phosphorylates NF-
 
 
 
B–associated I
 
 
 
B
 
 
 
, leading to its ubiq-
uitination and proteosomal degradation. These events release
NF-
 
 
 
B subunits in the cytosol, allowing them to travel to
the nucleus where they enhance transcription of target
genes. In mammals, the NF-
 
 
 
B family has five members:
RelA (p65), RelB, c-Rel, NF-
 
 
 
B1, and NF-
 
 
 
B2. RelA,
RelB, and c-Rel are synthesized as mature proteins, each
bearing a transcriptional transactivation domain and a
DNA-binding Rel homology domain. In contrast, the active
forms of NF-
 
 
 
B1 and NF-
 
 
 
B2, p50 and p52, are derived
from the full-length products of the 
 
nfkb1
 
 and 
 
nfkb
 
2 genes,
p105 and p100, respectively. The generation of the tran-
scriptionally active subunits p50 and p52 is dependent on
phosphorylation of their precursors followed by ubiquitina-
tion and partial proteosomal degradation of their COOH
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Abbreviations used in this paper: 
 
CTR, calcitonin receptor; EMSA, electro-
phoretic mobility shift assay; IKK, I
 
 
 
B kinase;
 
 
 
M
 
 
 
, bone marrow–derived
macrophages; M-CSF, macrophage CSF; MMP9, matrix metalloproteinase
9; NIK, NF-
 
 
 
B–inducing kinase; OC, osteoclast; RANK, receptor acti-
vator of NF-
 
 
 
B ligand; RANKL, RANK ligand; TRAP, tartrate-resistant
acid phosphatase.T
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termini (4, 5). The NH
 
2
 
-terminal Rel homology domain of
p50 or p52, when cleaved from the COOH terminus, can
form active NF-
 
 
 
B dimers with RelA, RelB, or c-Rel.
The COOH-terminal portions of p105 and p100, before
processing to p50 and p52, contain I
 
 
 
B-like ankyrin re-
peats. Thus, similar to I
 
 
 
B, p105 and p100 are capable of
retaining proteins with a Rel domain in the cytosol (6, 7).
p105 is ubiquitously expressed, and its conversion to p50
appears to be largely constitutive, with only modest in-
creases in levels of p50 in response to NF-
 
 
 
B activation (2).
In contrast, p100 is expressed predominantly in lymphoid
organs (8), and its processing is tightly controlled by a
kinase cascade. NF-
 
 
 
B–inducing kinase (NIK) activates
IKK
 
 
 
 (a subunit of the IKK complex), which phosphory-
lates p100, targeting it for processing to p52 (9, 10).
The importance of the NIK/IKK
 
 
 
/p100/p52 pathway
has been highlighted by several mouse models. The 
 
nfkb2
 
knockout mouse, which lacks both p100 and p52, exhibits
abnormal B cell differentiation and function (11, 12). Radia-
tion chimeras bearing IKK
 
 
 
 
 
/
 
 
 
 bone marrow or mice ex-
pressing nonactivatable IKK
 
  
 
have decreased p52 levels and
similar defects in B cell maturation (10). Alymphoplasia (aly/
aly) mice (13), which carry a mutation in the IKK
 
 
 
 interac-
tion domain of NIK (14, 15), also have diminished p52 lev-
els (9, 16) and defective B cell maturation (16). Finally, ani-
mals lacking the COOH-terminal I
 
 
 
B-like domain of
NF
 
 
 
B2, and which thus express unregulated p52, have in-
creased lymphocyte proliferation and gastric mucosal hyper-
plasia (17). In sum, these models demonstrate that regulated
expression of the active NF-
 
 
 
B subunit p52, via NIK- and
IKK
 
 
 
-mediated processing of p100, is biologically relevant.
Despite these findings, the importance of the putative in-
hibitory effect of unprocessed p100 on global NF-
 
 
 
B acti-
vation, via its I
 
 
 
B activity, has not been established. In this
study, we have used the NIK-deficient mouse (18) to ex-
amine the effects of a lack of p100 processing on OC dif-
ferentiation and NF-
 
 
 
B signaling. Previous studies of the
NIK/IKK
 
 
 
/p100 pathway in a physiological context have
only been performed in the B cell lineage, which is depen-
dent on p52 for full maturation (11, 12). The 
 
nfkb2
 
 knock-
out mouse, which lacks both p100 and p52, has normal
basal osteoclastogenesis in vivo (19), indicating that, in
contrast to its role in B cell development, p52 itself is dis-
pensable for OC differentiation. The fact that the NIK
 
 
 
/
 
 
 
mouse fails to process p100 to p52 positions us to examine
the potential role of p100 in osteoclastogenesis, in the ab-
sence of a requirement for p52. Our studies show that
when p100 levels are increased, as in NIK-deficient OC
precursors, RANKL-stimulated osteoclastogenesis is im-
paired. Conversely, we find that OC differentiation is en-
hanced in the absence of p100 in vitro. These results dem-
onstrate that stimulated osteoclastogenesis is regulated by a
pathway involving RANKL, NIK, and p100.
 
Materials and Methods
 
Mice.
 
NIK
 
 
 
/
 
 
 
 mice were generated by homologous recom-
bination as described (18) on a 129Sv/Ev background. Mice were
 
maintained by heterozygote matings in a specific pathogen-free
facility.
 
Osteoclast Culture.
 
For whole marrow culture, unfractionated
bone marrow cells were cultured in the presence of 1,25 dihy-
droxyvitamin D
 
3
 
 (2.5 
 
 
 
 10
 
 
 
8
 
 M) to induce osteoclast differentiation
(20). After 8 d, cultures were fixed and stained for tartrate-resis-
tant acid phosphatase (TRAP), a marker of OC differentiation,
according to manufacturer’s instructions (Sigma-Aldrich). To ob-
tain bone marrow–derived macrophages (M
 
 
 
), marrow cells
were on Petri dishes in the presence of CMG14–12 supernatant
containing the equivalent of 100 ng/ml recombinant M-CSF (21)
for at least 5 d. Equal numbers of WT and NIK
 
 
 
/
 
 
 
 M
 
 
 
s were re-
plated onto tissue culture plates in the presence of partially puri-
fied M-CSF (see M-CSF Preparation) equivalent to 20 ng/ml re-
combinant M-CSF and the indicated dose of GST-RANKL for
6 d and then fixed and stained for TRAP activity. For analysis of
resorptive activity, M
 
 
 
s were replated onto multiwell Osteologic
slides (BD Biosciences), which are coated with inorganic hy-
droxyapatite matrix, in the presence of M-CSF and 150 ng/ml
GST-RANKL. After 6 d, cells were fixed in neutral buffered for-
malin and stained with methylene blue.
 
In Vivo RANKL Treatment.
 
GST-RANKL was prepared as
described (22). WT and NIK
 
 
 
/
 
 
 
 mice (2–3 mo old) were in-
jected subcutaneously with GST-RANKL (500 
 
 
 
g per day for
7 d) or PBS (sham). Calvaria were fixed overnight in 10% buf-
fered formalin, decalcified in 14% EDTA, embedded in paraffin,
sectioned, and stained for TRAP with a hematoxylin counter-
stain. The number of OC per 10 fields (100
 
 
 
 magnification) for
five mice in each group was counted. Statistics were performed
with the unpaired Student’s 
 
t
 
 test.
 
Antibodies.
 
mAbs to RelA and the NH
 
2
 
 terminus of NF-
 
 
 
B2
common to p100 and p52 were from Santa Cruz Biotechnology,
Inc., as were the polyclonal antiserum directed against I
 
 
 
B
 
 
 
 and
RelB and the agarose conjugated anti-RelA polyclonal antibody
used for immunoprecipitation.
 
Semiquantitative RT-PCR.
 
Total RNA was extracted using
RNeasy (QIAGEN), and snf cDNA was generated with AMV-
RT (Fisher Scientific) according to manufacturers’ instructions
using 1 
 
 
 
g total RNA and oligo-dT primers diluted to a final
volume of 100 
 
 
 
l. Oligonucleotide primers used for PCR were:
nfkb2 sense, 5
 
 
 
-TGGCTGGTGGGGACTTGG-3
 
 
 
; nfkb2 anti-
sense, 5
 
 
 
-ACCCACCGAGATGTGGGC-3
 
 
 
; GAPDH sense,
5
 
 
 
-ACTTTGTCAAGCTCATTTCC-3
 
 
 
; GAPDH antisense,
5
 
 
 
-TGCAGCGAACTTTATTGATG-3
 
 
 
; calcitonin receptor
(CTR) sense 5
 
 
 
-CATTCCTGTACTTGGTTGGC-3
 
 
 
; CTR
antisense, 5
 
 
 
-AGCAATCGACAAGGAGTGAC-3
 
 
 
; matrix
metaloproteinase 9 (MMP9) sense, 5
 
 
 
-CCTGTGTGTTC-
CCGTTCATCT-3
 
 
 
; MMP9 antisense, 5
 
 
 
-CGCTGGAAT-
GATCTAAGCCCA-3
 
 ;   3 integrin sense, 5 -TTACCC-
CGTGGACATCTACTA-3 ; and  3 integrin antisense, 5 -
AGTCTTCCATCCAGGGCAATA-3 . For each reaction, 1–2
 l cDNA was used for the following PCR cycle numbers: nfkb2-
24; GAPDH-24; CTR-34; MMP9-24; and  3 integrin-30.
M-CSF Preparation. Supernatant was harvested from
CMG14–12 cells grown in phenol red–free media, diluted into
triethanolamine buffer, and loaded onto a Q sepharose Fast-
Flow column (Amerhsam Biosciences). M-CSF was eluted first
with a NaCl gradient (0–1.0 M), and then eluted from a second
Q column by pH gradient (pH 7 to 4). Peak fractions were di-
alyzed against PBS and sterile filtered. Bioactivity was com-
pared with recombinant murine M-CSF (R&D Systems) by as-
saying proliferation of M-NFS-60, an M-CSF–dependent cell
line (21).T
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Subcellular Fractionation. Cells were harvested by treatment
with 10 mM EDTA in PBS for 15–30 min at 4 C followed by
scraping. Nuclear and cytoplasmic fractions were isolated using
the NuCLEAR kit (Sigma-Aldrich). Extracts were quantitated by
a modified Coomassie method (Pierce Chemical Co.). For im-
munoblots, 5  g of nuclear extract or 25  g of cytoplasmic ex-
tract was used, and equivalent loading was verified by Ponceau
red staining after transfer to PVDF membrane.
NF- B DNA Binding Assays. For electrophoretic mobility
shift assay (EMSA), nuclear extracts (2  g) were incubated
with  labeled double stranded  B3 oligonucleotide (5 -AAA-
CAGGGGGCTTTCCCTCCTC-3 ) at 4 C for 32P-labeled
probes (see Figs. 4 and 5) or at room temperature for biotin-
labeled probes (see Fig. 8). Protein–DNA complexes were re-
solved on nondenaturing 4–20% polyacrylamide gels (Invitro-
gen) in 0.5   TBE. Radiolabeled gels were dried and subjected
to autoradiography. For nonradioactive detection, the LightShift
chemiluminescent system (Pierce Chemical Co.) was used, ac-
cording to manufacturer’s instructions, using a biotinylated ver-
sion of the same oligo (Invitrogen). For RelA supershift, 2  g
polyclonal anti-RelA (Santa Cruz Biotechnology, Inc.) was
added after formation of DNA–protein complexes at room tem-
perature for 15 min. An ELISA-based NF- B assay, the EZDe-
tect p65 ELISA (Pierce Chemical Co.) was performed according
to manufacturer instructions, using 2  g nuclear extract per well,
performed in triplicate. Background (extraction buffer alone, av-
eraged for three wells) was subtracted from each sample. In this
assay, nuclear extract is applied to wells precoated with specific
NF- B oligos followed by anti-p65 (RelA) antibody and an
HRP-conjugated secondary. The assay is developed with chemi-
luminescent substrates and read on a luminometer/plate reader
(SpectraFluor Plus; Tecan).
Retroviral Transduction. M  were transduced with retrovirus
containing vector alone (pMX-puro) (23) or a noncleavable form
of p100 (pMX-p100 GRR) for 24 h in the presence of
CMG14–12 supernatant equivalent to 200 ng/ml rM-CSF and 4
 g/ml polybrene (Sigma-Aldrich) and then selected with puro-
mycin for 3 d. Surviving M  were passaged on Petri dishes and
grown in M-CSF overnight before the preparation of nuclear ex-
tracts, or passaged into 96-well plates, cultured in M-CSF (20 ng/
ml) and GST-RANKL (150 ng/ml) for 5 d, and then fixed and
stained for TRAP activity.
Results
Stimulated Osteoclastogenesis Is Blunted in NIK /  Mice.
To determine if p100 processing has a role in OC differen-
tiation, we placed NIK /  (18) bone marrow cells in os-
teoclastogenic conditions and found they fail to generate
multinucleated cells expressing TRAP, a marker of the OC
phenotype (Fig. 1 A). In these whole marrow cultures,
stromal cells provide the M-CSF and RANKL required for
osteoclastogenesis. OCs can also be generated in vitro from
pure populations of M s treated with soluble recombinant
M-CSF and RANKL. As shown in Fig. 1 B, WT M s ex-
posed to these cytokines form confluent sheets of large,
spread OCs and exhibit exuberant resorptive activity (Fig.
1 C). In contrast, NIK /  cultures, although rich in M s,
contain only rare, poorly spread TRAP-positive cells (Fig.
1 B) with no detectable resorptive capacity (Fig. 1 C). The
lack of osteoclastogenesis in NIK /  cultures cannot be
Figure 1. NIK /  mice have defective RANKL-mediated osteoclas-
togenesis in vitro. (A) Equal numbers of WT and NIK /  cells from
unfractionated bone marrow were cultured for 8 d in the presence of
vitamin D3 and then fixed and stained for TRAP, a marker of OC dif-
ferentiation. Under these conditions, both stromal cells and OC precursors
are present. NIK /  cultures fail to form large, spread, TRAP-positive
OCs. Bar, 300  m. (B) Equal numbers of M s (expanded from bone
marrow in high doses of M-CSF) from WT and NIK /  mice were
cultured in the presence of M-CSF and the indicated dose of RANKL
for 6 d and then fixed and stained for TRAP. Very few, poorly spread
TRAP-positive cells are seen in the NIK /  cultures. Bar, 100  m. (C) Os-
teoclastogenic cultures were generated as in B on an artificial hydroxy-
apatite matrix (Osteologic slides). On day 6, cultures were stained with
methylene blue at basic pH. Resorbed matrix is seen as a clear white
area around dark cells. NIK /  cultures have negligible matrix resorp-
tion. Bar, 300  m. (D) WT and NIK /  M  s were treated with
RANKL for 0–4 d and then harvested for RNA extraction. Semiquan-
titative RT-PCR was performed for CTR, MMP9, and  3 integrin, all
markers of OC differentiation, with GAPDH as control. Although  3
integrin levels are comparable at day 1, all three markers show a failure
in induction from days 2–4 in NIK /  cultures, confirming the mor-
phological lack of differentiation.T
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rescued by increasing RANKL by amounts up to 10-fold
the optimal dose for WT cultures (Fig. 1 B, 1,000 ng/ml
RANKL) or by doubling the time in culture (unpublished
data). Given that these experiments were performed using
only M s, the osteoclastogenic defect in NIK /  whole
marrow cultures resides in OC precursors and not in cyto-
kine-producing stromal cells. The lack of morphological
changes in NIK /  cultures is accompanied by a failure,
beyond day 1, to up-regulate transcripts characteristic of
OCs, including  3 integrin, matrix metalloproteinase 9,
and CTR (Fig. 1 D). However, NIK /  cultures are not
completely unresponsive to RANKL. At day 1,  3 integrin
mRNA is induced in NIK /  cultures at levels similar to
WT. Additionally, NIK /  M s show normal MAPK acti-
vation (unpublished data).
Interestingly, in vivo basal osteoclastogenesis is unaltered
in NIK /  mice. Femurs of unmanipulated 3–4-mo-old
WT and NIK /  mice have similar cortical thickness, tra-
becular size and distribution, and number of osteoclasts (Fig.
2 A). On the other hand, and consistent with our in vitro
observations, these mutants exhibit a blunted response to os-
teoclastogenic stimuli. Whereas WT mice generate a robust
sevenfold increase in OC number along calvarial sinuses af-
ter 1 wk of RANKL treatment, NIK /  mice show only a
twofold rise (Fig. 2, B and C). Similarly, NIK /  mice fail
to show a significant osteoclastogenic response to a 3-d
course of parathyroid hormone injection (unpublished data).
RANKL Induces Processing of p100 in WT but not NIK / ,
OC Precursors. Because NIK has been shown to control
p100 processing in response to other TNF family cyto-
kines, we next assessed the effect of RANKL on p100 and
p52 levels in WT and NIK /  cultures. In unstimulated
WT M s (Fig. 3 A, 0 h), p100 but not p52 is readily de-
tected. Exposure to RANKL yields accumulation of p52
beginning at 4 h, with no change in p100 levels. In con-
trast, RANKL exposure for as long as 48 h fails to induce
the appearance of p52 in NIK /  OC precursors. More-
over, whereas basal p100 levels are comparable in WT and
NIK /  M s (0 h for WT and NIK /  in Fig. 3 A), p100
is substantially enhanced (2.5–4-fold) in mutant cells by 8 h
of RANKL exposure, and this increase persists for at least
48 h This effect is specific for RANKL, since exposure of
WT M  to TNF  does not induce production of p52, al-
though it does increase p100 levels (Fig. 3 B).
Because the nfkb2 gene is itself regulated by NF- B (24),
we asked if increased transcription contributes to the accu-
mulation of p100 in NIK-deficient cells. Semiquantitative
RT-PCR shows that RANKL treatment up-regulates
nfkb2 mRNA fourfold by 6 h in both WT and NIK / 
M  cultures (Fig. 3 C). Interestingly, nfkb2 mRNA levels
are substantially lower in NIK /  cells at 24 and 48 h. Be-
cause NF- B transactivates the nfkb2 gene, this observation
is consistent with a possible decrease in NF- B signaling at
these later times.
Figure 2. NIK /  mice have normal basal osteoclastogenesis and a
blunted response to RANKL in vivo. (A) TRAP-stained sections of
femurs from unmanipulated 3–4-mo-old WT and NIK /  mice show
no difference in trabecular architecture or OC number red-stained
cells. Bar, 600  m. (B) WT and NIK /  mice were injected with 500
 g GST-RANKL or PBS daily for 7 d and killed on the 8th day.
TRAP-stained coronal sections of calvaria adjacent to the sagittal suture
show a dramatic increase in OCs along sutures and sinusoids only in
WT RANKL-treated animals. Bar, 150  m. (C) Quantitation of osteo-
clasts along inner (sinusoidal) calvarial surfaces for animals described in
B confirms the significant difference in the response of WT and NIK / 
mice to RANKL injection. Error bars indicate SEM. *P   0.0001
compared with WT sham. **P   0.001 compared with NIK /  sham
and WT RANKL.T
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NF- B Signaling Is Intact in NIK /  M s but Blunted in
NIK /  preOCs. To determine whether the differences in
p100 processing between WT and NIK /  cultures impacts
NF- B signaling, we assessed NF- B activation in M s
(time 0 in Fig. 3 A in which WT and NIK /  cultures have
equivalent p100 levels) and preOCs (48 h in Fig. 3 A in
which NIK /  cultures have more p100 and no p52). Acute
stimulation of M s with RANKL led to normal degrada-
tion of I B , nuclear translocation of RelA, NF- B DNA
binding activity, and resynthesis of I B  (an NF- B–
dependent event) in NIK /  M  cultures (Fig. 4, A and B)
consistent with the findings of Yin et al. (18). In contrast,
RANKL stimulation of preOCs (generated by exposing
M s to RANKL for 48 h, then starving of serum and cyto-
kines for 3 h) has very different results in WT and NIK / 
cultures. Similar to its effects in M s (Fig. 4), RANKL
stimulation of WT preOCs leads to I B  degradation, nu-
clear translocation of RelA, and increased NF- B DNA
binding capacity (Fig. 5, A–C). NIK /  preOCs degrade
I B  in a manner similar to that of WT cells (Fig. 5 A), al-
though basal levels are a bit lower than WT. On the other
hand, RelA does not appear in nuclear extracts of the mu-
tant cells (Fig. 5 A). Concordantly, both basal and stimu-
lated NF- B DNA binding activity is decreased as assessed
by EMSA (Fig. 5 B) and an ELISA-based chemilumines-
cent assay for RelA-specific NF- B activation (Fig. 5 C).
In addition, resynthesis of I B  is blunted in the absence of
NIK (Fig. 5 A, 60 min).
To determine if the nuclear translocation of other NF-
 B subunits is affected in NIK /  cultures, we analyzed
nuclear extracts of WT and NIK /  M s and preOCs by
immunoblot (Fig. 6). As expected based on Fig. 3 A,
within 60 min of RANKL stimulation, neither WT nor
NIK /  M s have nuclear p52. Only WT preOCs contain
nuclear p52, and this is only slightly responsive to RANKL
stimulation. Additionally, RelB is present at high levels in
WT preOCs, at very low levels in WT M s, and absent in
NIK /  M s and preOCs.
These data indicate that, as in other cytokine signaling
pathways, NIK is not involved in the degradation of I B 
in response to RANKL. NIK does, however, play a per-
missive role in NF- B nuclear translocation in committed
preOCs, suggesting increased activity of another I B-like
protein in NIK-deficient preOCs but not M .
p100 Functions as an I B Protein in NIK /  preOCs.  To
determine if the enhanced p100 appearing in RANKL-
treated NIK /  preOCs functions as an I B, RelA was im-
munoprecipitated from resting or RANKL-stimulated pre-
OCs, and its association with p100 and I B  was assessed
by immunoblot (Fig. 7). As expected, RelA levels are simi-
lar in WT and NIK /  cells, and association of the subunit
with I B  is decreased by RANKL treatment in both cir-
cumstances. On the other hand, although p100 does not
associate with RelA in WT cells, it is readily detected in
resting NIK /  RelA immunoprecipitates, and this associa-
tion increases in response to RANKL. These data suggest
Figure 3. RANKL-induced p100 processing does not occur in NIK / 
OC precursors despite normal induction of nfkb2 transcription. (A) WT
and NIK /  M s were treated with RANKL for increasing times, and
total lysates were analyzed by immunoblot to detect changes in p100 and
p52 levels, using a monoclonal antibody recognizing the NH2 terminus
common to p100 and p52. The blot was stripped and reprobed with anti- 
actin as a loading control (bottom). In WT cultures, p100 levels remain
steady, whereas p52 levels are increased by RANKL treatment. Parallel
NIK /  cultures fail to generate p52 at any time point and accumulate
p100. (B) WT M s were treated with RANKL or TNF  for the indi-
cated times, and p100/p52 levels were assessed by immunoblot as in A.
p100 processing does not occur in response to TNF . (C) WT and
NIK /  M s were treated with RANKL for increasing times, and RNA
was harvested. Levels of nfkb2 mRNA were analyzed by semiquantitative
RT-PCR using GAPDH as a control. Numbers beneath lanes indicate
fold increase over WT 0 h baseline. Although WT and NIK /  cultures
show equivalent induction of nfkb2 at 6–12 h, levels are significantly
lower in NIK /  cultures thereafter.
Figure 4. NF- B signaling in NIK /  M s is intact. (A) M s were
acutely stimulated with RANKL for the indicated times, and cytoplasmic
(top) and nuclear (bottom) fractions were analyzed by immunoblot for
I B  and RelA, respectively. (B) NF- B DNA binding activity was as-
sessed at 0 and 15 min by EMSA using a  B3 oligonucleotide probe and
nuclear extracts from A. NF- B signaling is comparable in WT and
NIK /  M  cultures in response to RANKL.T
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that, in NIK /  OC precursors, exposure to RANKL re-
sults in accumulation of p100 because it cannot be pro-
cessed to p52. Accumulated p100 would then bind NF- B
subunits as they are released from I B , preventing their
nuclear translocation and the subsequent induction of gene
transcription. This model predicts that expression of a non-
processable form of p100 in WT OC precursors would in-
hibit osteoclastogenesis.
To test this hypothesis, we used a p100 construct,
p100 GRR, which lacks the glycine-rich region deter-
mining the site of proteosomal cleavage and hence cannot
be processed to p52 (5). Using the pMX-puro retroviral
vector (23), we expressed p100 GRR or vector alone as a
control in WT M s (Fig. 8 A). Cells transduced with pMX
or pMX-p100 GRR were stimulated with RANKL for
15 min, and NF- B DNA binding activity was assessed by
EMSA compared with unstimulated controls. Expression of
p100 GRR markedly inhibits induction of NF- B activ-
ity (Fig. 8 B). Transduced M s were also cultured in os-
teoclastogenic concentrations of RANKL plus M-CSF.
Consistent with the role of unprocessed p100 as an NF- B
inhibitory protein, expression of p100 GRR inhibits for-
mation of mature OCs (Fig. 8 C).
Finally, if, as we propose, p100 blunts RANKL-stimu-
lated osteoclastogenesis, OC precursors lacking p100 should
show enhanced sensitivity to RANKL. In fact, nfkb2 / 
M s (which lack both p100 and p52) form OCs at lower
doses of RANKL and with shorter exposure to the cyto-
kine compared with WT controls (Fig. 9). These data con-
firm that the nfkb2 gene product p100 has an inhibitory
effect on RANKL-stimulated osteoclastogenesis, although
p52, which potentially contributes to total NF- B signal-
ing, is dispensable.
Discussion
OCs are uniquely capable of degrading both the organic
and inorganic components of bone, and in concert with
bone-building osteoblasts are required for maintenance of
skeletal integrity and mineral homeostasis (1). Stimulated
OC recruitment prompts the skeletal lesions of postmeno-
pausal osteoporosis, rheumatoid arthritis, and osteolytic
metastasis of malignant tumors. Unlike the mesenchyme-
Figure 5. NF- B does not accumulate in the nucleus of NIK /  preOCs.
(A) PreOCs, generated by treating M s with RANKL for 48 h followed
by a 3 h starvation, were stimulated with RANKL for the indicated times,
and cytoplasmic (top) and nuclear (bottom) fractions were isolated and
analyzed by immunoblot for I B  and RelA, respectively. Although
I B  gets degraded in both WT and NIK /  cultures, RelA does not
accumulate in the nucleus in the absence of NIK. (B) Nuclear extracts
prepared as in A were analyzed for NF- B DNA binding activity by
EMSA. Whereas WT preOC cultures have detectable NF- B activity at
baseline and further induction by RANKL, NIK /  preOC cultures
show little binding activity with or without RANKL. (C) RelA-specific
NF- B DNA binding activity was assessed by ELISA (EZ Detect kit;
Pierce Chemical Co.) using the same preOC nuclear extracts as in A. In
this assay, NF- B–specific oligos are bound to a plate. Nuclear extract is
then applied followed by anti-p65 (RelA) antibody and an HRP-conjugated
secondary. The assay is developed with chemiluminescent reagents and
read on a luminometer/plate reader. Each sample was run in triplicate.
Unmutated (UnMu) and mutant (Mu) soluble oligos were added to the
WT 30-min sample to confirm specificity. The results of this assay mirror
the EMSA in B and confirm lower baseline NF- B activity and lack of
RANKL-mediated induction in NIK /  preOCs. Binding activity is
abolished by addition of the unmutated oligo and unaffected by the mutant
oligo (last two bars).
Figure 6. RelB and p52 fail to accumulate in the nucleus in NIK / 
preOCs. Immunoblot of nuclear extracts from M  and preOC cultures
treated acutely with RANKL shows accumulation of p52 only in WT
preOCs (top). Levels of nuclear RelB are highest in WT preOCs, with
minimal acute induction by RANKL. WT M s show low levels of nuclear
RelB, whereas NIK /  M s and preOCs lack this NF- B subunit. A
background band (bkgd) in RelB immunoblots shows equivalent signal in
all lanes.
Figure 7. Association of RelA
and p100 is increased in NIK / 
preOCs. PreOCs (generated as
in Fig. 5) were starved for 3 h
and restimulated with RANKL
for the indicated times before lysis.
Total lysates were immunopre-
cipitated with anti-RelA anti-
body and analyzed by immunoblot
for p100, RelA, and I B . In both WT and NIK / cultures, association
of RelA and I B  were reduced upon RANKL treatment. In WT cells,
RelA associates with p100 only transiently. In contrast, RelA is bound to
p100 in NIK /  cultures before addition of RANKL, and this association
is increased with RANKL treatment as I B  is degraded.T
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derived osteoblasts that survive for several months, bone
marrow–derived OCs are short-lived with a lifespan of 1–2
wk (25). Therefore, tight control of OC differentiation is as
critical as control of OC activity for skeletal homeostasis.
NF- B is potently induced by RANKL in OC precursors
(26), and the occurrence of osteopetrosis, with an early
block in osteoclastogenesis, in nfkb1/nfkb2 double knockout
mice established the importance of this signal (19, 27). Indi-
vidual ablation of either nfkb1 or nfkb2 does not impact the
skeleton of unmanipulated mice, indicating mutual compen-
sation between p50 and p52. In vitro osteoclastogenesis, by
coculture with osteoblasts, is also not impaired in either
nfkb1- or nfkb2-deficient mice (19). nfkb1 /  and nfkb2 / 
mice lack both the precursor (p105 or p100) and the active
NF- B subunit (p50 or p52). Due to the potential opposing
functions of the precursors (as I Bs) and the products (as ac-
tive NF- Bs), loss of both precursor and product may mask
the function of either one. Thus, the impact of individual
subunits on specific NF- B targets, or on a physiological
process such as osteoclastogenesis, is unresolved.
The conversion of p105 to p50 is predominantly consti-
tutive, and no specific regulators of the process are in hand
(4). In contrast, processing of p100 to p52 is tightly con-
trolled by a known signaling pathway involving NIK (9,
10). Therefore, by manipulating this pathway it is possible
to substantially alter the ratios of these two proteins. For in-
stance, in the absence of processing, increased transcription
of the nfkb2 gene can enhance p100 levels. When both
synthesis and processing of p100 are stimulated, p52 levels
rise while p100 levels remain stable, greatly increasing the
ratio of p52 to p100. We have used the NIK /  system in
which p100 accumulates due to an absence of processing
and have uncovered a requirement for the processing of
p100 for RANKL-stimulated osteoclastogenesis.
NIK directly interacts with TRAFs (28), a family of
adaptors that mediate NF- B and JNK activation down-
stream of TNF receptor family members, including
RANK, CD40, and Lt R. Although overexpression stud-
ies suggested that NIK is the kinase bridging this receptor/
adaptor family and the classical NF- B cascade (via its di-
rect interaction with IKKs) (29), this role is not supported
Figure 8. Expression of a noncleavable form of p100 in WT M s
inhibits NF- B signaling and osteoclastogenesis. (A) WT M s were
transduced with retrovirus bearing empty pMX or pMX-p100 GRR, a
noncleavable form of p100, overnight and selected in puromycin for 3 d
before lysis. Immunoblots for p100/p52 demonstrate expression of the
retroviral driven p100 GRR (lane 2) at levels three to fourfold above
endogenous p100 (lane 1), similar to that seen in RANKL-treated NIK / 
M s. (B) NF- B activity was assessed by EMSA on M s transduced with
pMX (control) or pMX-p100 GRR as above. Lanes 1–2, cells trans-
duced with pMX, unstimulated (lane 1), or treated with RANKL for 15
min (lane2); lanes 3–4, cells transduced with pMX-p100 GRR, unstim-
ulated (lane 3), or treated with RANKL for 15 min (lane 4); lane 5,
RANKL-stimulated vector control, with unlabeled probe at 50-fold ex-
cess; and lane 6, RANKL-stimulated vector control supershifted with
polyclonal anti-RelA antibody. The supershifted band is indicated (ss).
Expression of p100 GRR in M s dramatically decreases NF- B signal-
ing by RelA in response to RANKL. (C) After the 3 d puromycin selection,
retrovirally transduced M s were cultured in RANKL for 5 d and then
stained for TRAP. Expression of p100 GRR inhibits osteoclastogenesis
in these WT cultures. Bar, 300  m.
Figure 9. RANKL-mediated osteoclastogenesis in vitro is enhanced in
the absence of p100. M s from WT (A) and nfkb2 /  (B) mice were cul-
tured with increasing doses of GST-RANKL for 3, 4, or 5 d and then
fixed and stained for TRAP. The number of mature OCs was counted
for one 4  field per well, 4 wells per condition. At high doses of
RANKL (50–150 ng/ml), WT OCs begin to form on day 4 and are con-
fluent on day 5. In contrast, nfkb2 /  OCs begin to form on day 3 with
as little as 25 ng/ml RANKL and are confluent on day 4. The peak num-
bers of OCs are slightly lower for nfkb2 /  cultures than for WT cultures
because the nfkb2 /  OCs are larger. This is also the case for the nfkb2 / 
cultures at 25 ng/ml RANKL on day 5 in which the OCs are smaller
than at the higher doses. Thus, nfkb2 /  cultures, which lack both p100
and p52, show accelerated osteoclastogenesis at lower doses of RANKL
compared with WT controls.T
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by data from the alymphoplasia and NIK /  mice, which
do not exhibit a global defect in NF- B signaling (14, 18,
30). Furthermore, NIK, which binds to and activates
IKK , is specifically required for the processing of p100 to
p52 (9). The similar defects in NIK-, IKK -, and nfkb2-
deficient mice indicate that the p100 to p52 pathway is
critical for B cell maturation (10–12, 16, 18). BAFF, a TNF
family member, has been shown recently to activate this
pathway in B cells (31).
In the OC lineage, we find that p100 processing is initi-
ated by RANKL and promotes osteoclastogenesis. Other
RANKL-mediated signaling events, including activation of
JNK and ERK and degradation of I B , occur within
5–15 min of cytokine–receptor interactions (32). NIK, IKK ,
and p100 are all present in unstimulated OC precursors,
but p100 processing is not detectable before 4–6 h after ex-
posure to RANKL. Blockade of protein translation with
cyclohexamide also prevents p100 processing (33, 34 and
unpublished data). It is therefore likely that several inter-
mediary events, including protein translation, occur be-
tween RANK activation and NIK-mediated p52 expres-
sion, leading to a several hour delay.
We and others find that induction of p100 processing is
restricted to a subset of TNF family cytokines, including
RANKL, BAFF, and CD40L but not TNF  or IL-1  (31,
33, 34 and this article). Although TNF  can synergize
with RANKL to enhance osteoclastogenesis when added
after 48 h or RANKL exposure, it inhibits OC differentia-
tion if added simultaneously (35). The TNF -mediated
increase in p100 levels, without generation of p52, seen in
Figure 10. Model for p100-mediated blockade
of NF- B signaling in NIK-deficient preOCs. See
Discussion.T
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M  (Fig. 3 B) may explain the initial inhibitory effect of
TNF at early stages of osteoclastogenesis. The clear stimu-
latory effect of TNF  on OCs in vivo is not easily ex-
plained. However, other factors present in inflammatory
conditions may counteract the p100 effect, allowing the
many signals common to TNF  and RANKL, such as ac-
tivation of the classical NF- B pathway, MAPKs, and
PI3K, to act unopposed.
The features of the NIK/IKK /p100 pathway in the
OC lineage distinguish it from all previous descriptions of
the NF- B pathway. We propose (Fig. 10) that RANKL
induces degradation of I B , releasing NF- B, predomi-
nantly as RelA/p50 dimers, to rapidly accumulate in the
nucleus. After several hours, RANKL also stimulates NIK
to process p100, thus releasing p52, which can then com-
plex with RelA or with RelB and travel to the nucleus (36,
37). This transcriptionally active pool of nuclear NF- B
stimulates osteoclastogenesis. In the absence of NIK, NF-
 B signaling in OC precursors is initially intact. However,
after 1–2 d of RANKL stimulation sufficient p100 accu-
mulates in the cytosol to bind RelA/p50 dimers as they are
released from I B . This cytoplasmic retention of NF- B
combined with the lack of p52 reduces NF- B–mediated
transcription in the nucleus and inhibits osteoclastogenesis.
In vitro, the defect in RANKL-mediated osteoclastoge-
nesis in NIK /  cultures is profound. In vivo, NIK-defi-
cient mice are resistant to stimulated osteoclastogenesis in
response to injection of RANKL or parathyroid hormone
but show no bone phenotype in the basal state. Alympho-
plasia mice, like NIK /  mice, have normal bone architec-
ture and a striking defect in osteoclastogenesis in vitro (un-
published data). Mice lacking p100 (nfkb2 / ) also show no
basal bone phenotype, despite a pronounced enhancement
of RANKL-mediated osteoclastogenesis in vitro. Two
general possibilities present themselves to explain the ap-
parent paradox in the in vivo and in vitro phenotypes.
First, culture conditions may mirror stimulated but not
basal osteoclastogenesis. Second, because of compensatory
mechanisms operating in vivo, many knockout mice ex-
hibit no phenotype until stressed. As regards to the present
situation, although M-CSF and RANKL are necessary for
osteoclastogenesis in vivo and sufficient for differentiation
of pure OC precursors in vitro, other cytokines modulate
osteoclastogenesis within the bone microenvironment. For
example, TNF , in the context of permissive levels of
RANKL, enhances osteoclastogenesis in many inflamma-
tory conditions (35, 38–40) and also supports a normal
level of basal osteoclastogenesis via the p55 TNF receptor
(41). TGF  can also support RANKL-mediated osteoclas-
togenesis (42, 43). In fact, a combination of RANKL,
TNF , and TGF  rescues the NIK /  defect in osteoclas-
togenesis in vitro (unpublished data). We suspect that the
presence of these factors, and perhaps others in the bone
microenvironment, allows OC differentiation to occur at a
normal basal rate in NIK /  mice but cannot compensate
for the inhibitory influence of accumulated p100 induced
by exogenous RANKL or PTH, which exerts its osteoclas-
togenic effect through RANKL.
Our studies uncover a novel NF- B pathway using
RANKL-induced processing of p100 to control the pool of
inhibitory I B proteins. Whereas p100 processing is also
regulated in B cells by NIK, it is increased p52 and not de-
creased p100 that is critical for B cell maturation (10, 17).
Interestingly, p52 itself is dispensable for osteoclastogenesis,
since the nfkb2-deficient mouse, which lacks both p100
and p52, has normal OC numbers in vivo (19) and in-
creased OC numbers in vitro (Fig. 9). In addition, regu-
lation of NF- B signaling by p100 is distinct from the
classical I B pathway in both kinetics (hours versus min-
utes) and upstream regulation (IKK complex versus NIK/
IKK ). Thus, these two distinct mechanisms for NF- B
control (I B  degradation and p100 processing) allow for
cell type and receptor-specific responses within the NF- B
pathway.
NIK /  osteoclastogenesis in vivo is not impaired in the
basal state but only in conditions of excess RANKL such as
accompanies administration of PTH. This observation leads
us to propose that the modulating effect of NIK/p100 on
osteoclastogenesis is important in clinical conditions of in-
creased osteoclastogenesis, such as osteoporosis, rheumatoid
arthritis, and osteolytic bone metastasis, in which RANKL
expression is enhanced. Most importantly, the fact that
p100 arrests stimulated osteoclastogenesis makes it a poten-
tial therapeutic target in diseases of accelerated bone loss.
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